CO2024004211A2 - Formulaciones de proteínas quiméricas de factor viii y usos de las mismas - Google Patents

Formulaciones de proteínas quiméricas de factor viii y usos de las mismas

Info

Publication number
CO2024004211A2
CO2024004211A2 CONC2024/0004211A CO2024004211A CO2024004211A2 CO 2024004211 A2 CO2024004211 A2 CO 2024004211A2 CO 2024004211 A CO2024004211 A CO 2024004211A CO 2024004211 A2 CO2024004211 A2 CO 2024004211A2
Authority
CO
Colombia
Prior art keywords
factor viii
formulations
chimeric factor
viii proteins
polypeptide
Prior art date
Application number
CONC2024/0004211A
Other languages
English (en)
Spanish (es)
Inventor
Tyler Carlage
Randall Mauldin
Timothy R Mccoy
Loubna Mzaalak Tazi
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CO2024004211A2 publication Critical patent/CO2024004211A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CONC2024/0004211A 2021-10-15 2024-04-04 Formulaciones de proteínas quiméricas de factor viii y usos de las mismas CO2024004211A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256432P 2021-10-15 2021-10-15
PCT/US2022/078097 WO2023064886A1 (en) 2021-10-15 2022-10-14 Formulations of factor viii chimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
CO2024004211A2 true CO2024004211A2 (es) 2024-04-18

Family

ID=84362012

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0004211A CO2024004211A2 (es) 2021-10-15 2024-04-04 Formulaciones de proteínas quiméricas de factor viii y usos de las mismas

Country Status (12)

Country Link
US (1) US20240358800A1 (https=)
EP (1) EP4415693B1 (https=)
JP (1) JP2024538091A (https=)
KR (1) KR20240082408A (https=)
CN (1) CN118103034A (https=)
AU (1) AU2022366974A1 (https=)
CA (1) CA3229979A1 (https=)
CO (1) CO2024004211A2 (https=)
IL (1) IL311969A (https=)
MX (1) MX2024004494A (https=)
TW (1) TW202334244A (https=)
WO (1) WO2023064886A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
PL3793588T3 (pl) * 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Also Published As

Publication number Publication date
EP4415693A1 (en) 2024-08-21
JP2024538091A (ja) 2024-10-18
MX2024004494A (es) 2024-07-15
CA3229979A1 (en) 2023-04-20
CN118103034A (zh) 2024-05-28
KR20240082408A (ko) 2024-06-10
EP4415693C0 (en) 2026-02-18
EP4415693B1 (en) 2026-02-18
US20240358800A1 (en) 2024-10-31
TW202334244A (zh) 2023-09-01
WO2023064886A1 (en) 2023-04-20
AU2022366974A1 (en) 2024-05-30
IL311969A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
BR112023003010A2 (pt) Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
CL2022000094A1 (es) Anticuerpos anti-cd63, conjugados y usos de estos (divisional de la solicitud no. 202002965)
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
JOP20210084A1 (ar) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (glp1) وعامل تمايز النمو 15 (gdf15) واستخدامها
CO2020014566A2 (es) Métodos de tratamiento de la hemofilia a
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
SE8103594L (sv) N-(vinblastin-23-oyl)aminosyraderivat
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
CO2023017358A2 (es) Formulaciones de proteínas quiméricas del factor viii y usos de las mismas
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
CO2023000048A2 (es) Conjugados de citoquina
MX2024007198A (es) Factor genetico para aumentar la expresion de las proteinas recombinantes.
BR0014183A (pt) Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada
CO2024004211A2 (es) Formulaciones de proteínas quiméricas de factor viii y usos de las mismas
ES2185630T3 (es) Nuevos polipeptidos y peptidos, acidos nucleicos que los codifican, y su utilizacion en el campo de la terapia de tumores, inflamacion o inmunologia.
MX2020003810A (es) Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
WO2004071420A3 (en) Compositions and methods for less immunogenic protein formulations